{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Reliable protein-protein docking with AlphaFold, Rosetta, and replica-exchange\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Reliable protein-protein docking with AlphaFold, Rosetta, and replica-exchange\" presents a novel approach to improve protein-protein docking predictions by integrating AlphaFold-multimer (AFm) with a physics-based docking algorithm, ReplicaDock 2.0, resulting in a pipeline called AlphaRED (AlphaFold-initiated Replica Exchange Docking). The study addresses the limitations of current protein complex prediction methods, particularly in cases involving significant conformational changes, and demonstrates the efficacy of AlphaRED in improving docking accuracy, especially for challenging targets like antibody-antigen complexes.\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders\n\n1. **Integration with AlphaFold**: The study highlights the integration of AlphaFold's deep learning capabilities with Rosetta's physics-based docking approach. This combination leverages AlphaFold's ability to generate structural templates and Rosetta's capacity to refine these templates through enhanced sampling, addressing the challenge of predicting protein interfaces with significant conformational changes.\n\n2. **ReplicaDock 2.0**: This is a key component of the AlphaRED pipeline, which employs replica exchange Monte Carlo simulations to explore the conformational landscape of protein complexes. It focuses on capturing binding-induced conformational changes, which are crucial for accurately modeling interactions between nanobodies and the SARS-CoV-2 spike protein.\n\n3. **Docking Accuracy and Flexibility**: The study demonstrates that AlphaRED significantly improves docking accuracy over AlphaFold-multimer alone, particularly for targets with high conformational flexibility. This is achieved by using Rosetta's induced-fit docking strategy, which allows for backbone and side-chain flexibility, essential for modeling the dynamic interactions of nanobodies with viral proteins.\n\n4. **Performance on Antibody-Antigen Targets**: The paper reports a substantial improvement in docking success rates for antibody-antigen complexes, including nanobodies, with AlphaRED achieving a 51% success rate compared to AlphaFold-multimer's 19%. This is particularly relevant for designing nanobody binders against SARS-CoV-2, where accurate modeling of the antibody-antigen interface is critical.\n\n5. **Interface-pLDDT Metric**: The study introduces the interface-pLDDT metric, derived from AlphaFold's confidence scores, to assess docking accuracy. This metric helps identify flexible regions and guide the docking process, enhancing the prediction of binding orientations and improving the design of nanobody binders.\n\n6. **Computational Efficiency**: While Rosetta's physics-based methods are computationally intensive, the integration with AlphaFold allows for a more efficient exploration of the protein energy landscape. This balance between deep learning and physics-based sampling provides a feasible approach for high-throughput screening of potential nanobody candidates.\n\n7. **Application to SARS-CoV-2**: The insights gained from this study can be directly applied to the design of nanobodies targeting the SARS-CoV-2 spike protein. By accurately predicting the binding interfaces and accommodating conformational changes, the AlphaRED pipeline can aid in the development of effective therapeutic antibodies.\n\nIn summary, the integration of Rosetta's docking capabilities with AlphaFold's structural predictions in the AlphaRED pipeline offers a powerful tool for designing nanobody binders against challenging targets like the SARS-CoV-2 spike protein. This approach enhances docking accuracy, accommodates conformational flexibility, and provides a robust framework for high-throughput antibody design."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2\" presents a novel computational approach to design multivalent protein drugs targeting the SARS-CoV-2 spike protein. The study focuses on engineering trivalent microproteins that can bind simultaneously to the three receptor-binding domains (RBDs) of the spike protein, enhancing their neutralizing activity against the virus.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Role of RosettaRemodel**: \n   - RosettaRemodel was employed to design linkers connecting the C-terminus of miniACE2 and the N-terminus of the trimerization scaffold. This tool samples backbone conformations by incorporating fragments from a database of known protein structures, guided by Ramachandran restraints and clash avoidance.\n   - The blueprint file in RosettaRemodel specified the connectivity, secondary structure, and sequence of the linker regions. The \"0\u00d7L\" entries allowed backbone flexibility for fragment insertion, and the linker sequence was specified to match the desired connectivity.\n\n2. **Linker Design and Optimization**:\n   - The study tested (GGGGS)n and (EAAAK)n linkers with varying repeat numbers (n = 2, 3, 4, and 5) to determine optimal structures. The \"-no_jumps\" flag was used to control the folding process within the linker, enabling sampling of degrees of freedom in the connecting region.\n   - For each linker candidate, 1000 independent trajectories were sampled, and the lowest-energy models were saved as PDB files. This process helped identify linkers that provided the necessary geometric matching for effective trimerization.\n\n3. **Computational Evaluation**:\n   - The initial 3D structures of the trivalent constructs were modeled using SWISS-MODEL, and all-atom molecular dynamics (MD) simulations were performed using GROMACS with the AMBER 99SB-ILDN force field.\n   - Free energy landscapes (FELs) were constructed to map possible conformations and energy levels, using principal component analysis (PCA) to project simulated conformations onto principal components.\n\n4. **Binding Free Energy Calculations**:\n   - The gmx_MMPBSA package was used to calculate the binding free energy of the monomers of the trivalent proteins via the MM/GBSA method. This helped rank the self-assembly abilities of different constructs.\n\n5. **Experimental Validation**:\n   - The designed constructs were expressed in E. coli Rosetta (DE3) cells and purified for experimental validation. Size-exclusion chromatography (SEC) and Native-PAGE analyses were used to evaluate their oligomeric states and conformational homogeneity.\n\n6. **Cryo-EM Structural Analysis**:\n   - The cryo-EM structure of the Tr67-Omicron BA.1 spike complex confirmed that Tr67 binds to all three RBDs of the spike protein in a synergistic manner, inducing the \"3-RBD-up\" conformation.\n\n### Conclusion:\nThe study demonstrates the effectiveness of using computational tools like RosettaRemodel in the rational design of multivalent protein drugs. By optimizing linkers and trimerization scaffolds, the researchers successfully engineered trivalent microproteins with enhanced binding affinities and neutralizing activities against SARS-CoV-2 variants. The approach provides a framework for designing multivalent therapeutics targeting other disease proteins, offering a promising strategy for combating rapidly evolving viruses like SARS-CoV-2."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Structural evolution of Delta lineage of SARS-CoV-2\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Structural evolution of Delta lineage of SARS-CoV-2\" provides a comprehensive analysis of the structural and biological changes in the B.1.617.2 (Delta) variant of the SARS-CoV-2 Spike protein. The study employs a variety of computational biology techniques, including molecular dynamics (MD), immunoinformatics, and molecular docking, to understand the implications of mutations in the Delta variant on its structure, stability, and interaction with antibodies and potential therapeutics.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta's Role in Antibody Design:**\n   - The study utilizes the Rosetta software suite, a powerful tool for protein modeling and design, to enhance the stability and affinity of the Bamlanivimab antibody against the Delta variant's Spike protein.\n   - Rosetta's antibody design protocol was employed to redesign the Bamlanivimab-Spike complex, focusing on improving interactions with the mutated Spike protein.\n\n2. **Design Process:**\n   - The process involved optimizing the backbone and sidechains of the antibody to resolve structural clashes using Rosetta's Relax and Repack modules.\n   - A resfile was created to identify hot spots (residues at the Spike-ACE2 interface within 7 \u00c5) for targeted design, allowing all natural residues to be considered for these positions.\n\n3. **Affinity and Stability Improvement:**\n   - The Rosetta design protocol generated over 1000 antibody structures, identifying seven variants with improved interaction potential compared to the native Bamlanivimab.\n   - The redesigned antibodies showed better binding scores, indicating enhanced affinity for the Delta variant's Spike protein.\n\n4. **Impact of Mutations:**\n   - The study highlights how specific mutations in the Delta variant, such as L452R and T478K, affect the Spike protein's conformation and interaction with ACE2, enhancing its binding affinity.\n   - Rosetta's docking protocol revealed that these mutations improve the spatial arrangement of interface residues, facilitating stronger interactions with ACE2.\n\n5. **Free Energy Calculations:**\n   - Rosetta's Score module was used to assess the energy of the native and mutant Spike structures, showing that the mutant Spike achieved a more optimal energy state, indicating increased stability.\n   - The binding free energy of the Spike-ACE2 complex was also evaluated, confirming the enhanced affinity of the mutant Spike for ACE2.\n\n6. **Potential for Nanobody Design:**\n   - The insights gained from using Rosetta for antibody design can be extended to nanobody development, focusing on targeting the RBD of the Spike protein to prevent virus entry.\n   - The study suggests that computationally designed antibodies or nanobodies could offer effective therapeutic options against emerging variants like Delta.\n\nOverall, the paper demonstrates the utility of Rosetta in designing antibodies with improved efficacy against SARS-CoV-2 variants, emphasizing its role in addressing the challenges posed by viral mutations. The findings underscore the potential of computational approaches in guiding the development of next-generation therapeutics for COVID-19."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"The Role of Rigid Residues in Modulating TEM-1 \u03b2-Lactamase Function and Thermostability\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"The Role of Rigid Residues in Modulating TEM-1 \u03b2-Lactamase Function and Thermostability\" explores the relationship between protein dynamics and enzymatic function, specifically focusing on TEM-1 \u03b2-lactamase. The study investigates how rigid residues, which are allosterically coupled to the active site, influence enzyme function and stability. The Rosetta software suite was employed to design mutations around these rigid residues to assess their impact on the enzyme's properties.\n\n### Key Insights on Rosetta and Its Application to SARS-CoV-2 Nanobody Design:\n\n1. **Rosetta Software Suite**: \n   - Rosetta is a powerful computational tool used for protein design and prediction. In this study, it was utilized to mutate amino acids around rigid residues in TEM-1 \u03b2-lactamase to explore their effects on enzyme function and stability.\n   - The software employs a Monte Carlo sampling protocol to explore different residue identities and conformations, assessing the fitness of mutated proteins using an energy function.\n\n2. **Design Strategy**:\n   - The study focused on two types of residues: rigid residues highly coupled to the active site and flexible residues with no apparent communication with the active site.\n   - Mutations were introduced around these residues using Rosetta to create \"design spheres,\" allowing for the exploration of chemical properties without compromising protein folding.\n\n3. **Impact on Protein Dynamics**:\n   - Alterations around rigid residues significantly affected enzymatic activity and stability, while changes around flexible residues maintained native-like properties.\n   - This suggests that rigid residues play a crucial role in protein dynamics and can influence function through allosteric coupling.\n\n4. **Application to SARS-CoV-2 Nanobody Design**:\n   - The insights gained from this study can be applied to the design of nanobodies targeting the SARS-CoV-2 spike protein.\n   - By identifying rigid residues in the spike protein that are allosterically coupled to the binding site, Rosetta can be used to design nanobodies that optimize binding affinity and stability.\n   - The approach of targeting rigid, allosterically coupled residues could enhance the efficacy of nanobodies by modulating the dynamics of the spike protein to favor binding.\n\n5. **Dynamic Distance Analysis (dda)**:\n   - A novel metric developed in the study, dda, measures the \"dynamic distance\" between proteins, providing insights into their dynamic profiles.\n   - This method could be used to evaluate the dynamic compatibility of designed nanobodies with the SARS-CoV-2 spike protein, ensuring effective binding and neutralization.\n\n6. **Broader Implications**:\n   - The study highlights the importance of understanding protein dynamics in drug design, suggesting that targeting dynamic hubs can lead to significant functional changes.\n   - This approach could be extended to other proteins and pathogens, offering a general strategy for designing therapeutics that exploit protein dynamics.\n\nIn summary, the use of Rosetta in this study demonstrates its potential for designing protein variants with altered dynamics and function. The insights gained can be directly applied to the design of nanobodies against SARS-CoV-2, focusing on rigid residues that influence protein dynamics and function through allosteric coupling. This approach could lead to the development of more effective therapeutics by leveraging the dynamic properties of target proteins."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Mutations in spike protein and allele variations in ACE2 impact targeted therapy strategies against SARS-CoV-2\" explores the challenges posed by genetic variations in the SARS-CoV-2 spike protein and the human ACE2 receptor in developing effective therapies for COVID-19. The study emphasizes the complexity of targeting these proteins due to mutations that can enhance viral infectivity and affect drug efficacy across different populations.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta Software Utilization**:\n   - The study employed Rosetta software, specifically the RosettaDock and FlexPepDock modules, to refine complex structures of the spike-S1 protein and ACE2 receptor. This computational tool was crucial in predicting and optimizing the binding interactions between the spike protein and potential therapeutic molecules, including nanobodies.\n\n2. **Structural Refinement and Interaction Scoring**:\n   - Rosetta was used to refine the initial coarse models of the spike-S1-ACE2 complexes. The final structures were determined based on energy scores calculated by Rosetta, which provided insights into the binding affinities and potential efficacy of nanobody candidates.\n\n3. **Energy and Interaction Analysis**:\n   - The study highlighted the importance of energy and interaction scores in evaluating the binding potential of spike-S1 mutants (such as V354F and V470A) to ACE2. Rosetta's scoring functions helped identify mutations that could lead to increased infectivity by enhancing the spike protein's binding affinity to ACE2.\n\n4. **Designing Nanobody Binders**:\n   - By using Rosetta to model and assess the structural dynamics of spike protein variants, the study provided a framework for designing nanobody binders that could effectively target these mutations. The software's ability to simulate protein-protein interactions allowed researchers to predict how nanobodies might bind to and neutralize the virus.\n\n5. **Implications for Therapeutic Development**:\n   - The insights gained from Rosetta simulations underscored the need for adaptable therapeutic strategies that consider the evolving genetic landscape of SARS-CoV-2. The study suggested that nanobodies designed using Rosetta could be tailored to target specific spike protein mutations, potentially offering a more robust response to emerging viral variants.\n\nOverall, the use of Rosetta in this study exemplifies how computational tools can guide the design and optimization of nanobody binders, providing a critical step toward developing effective therapies against SARS-CoV-2, especially in the face of ongoing viral mutations."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"De novo design of protein structure and function with RFdiffusion\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"De novo design of protein structure and function with RFdiffusion\" presents a novel approach to protein design using a deep-learning framework called RFdiffusion. This framework leverages the RoseTTAFold (RF) structure prediction network, fine-tuned for protein structure denoising tasks, to create a generative model capable of designing diverse protein structures and functions. The paper highlights several key insights, particularly in relation to the Rosetta software suite and its application in designing SARS-CoV-2 nanobody binders.\n\n### Key Insights on Rosetta and SARS-CoV-2 Nanobody Design:\n\n1. **Rosetta's Role in Protein Design:**\n   - Rosetta is a well-established computational tool for protein structure prediction and design. It has been used extensively for de novo protein design, including the design of protein binders.\n   - The traditional Rosetta-based methods involve physically-based modeling and require extensive sampling and screening of thousands of designs to identify high-affinity binders.\n\n2. **Limitations of Traditional Rosetta Methods:**\n   - Despite its success, Rosetta's approach to binder design is limited by the need to pre-specify protein scaffolds, which restricts the diversity and shape complementarity of potential solutions.\n   - The experimental success rates using Rosetta have been relatively low, necessitating the screening of a large number of designs to find effective binders.\n\n3. **RFdiffusion as an Advancement:**\n   - RFdiffusion represents a significant advancement over traditional Rosetta methods by using a diffusion model fine-tuned on protein structure denoising tasks.\n   - This approach allows for the generation of binding proteins directly in the context of the target, without the need for pre-specified scaffolds, thus increasing the diversity of potential solutions.\n\n4. **Designing SARS-CoV-2 Nanobody Binders:**\n   - The paper demonstrates the application of RFdiffusion in designing trimeric multivalent binders to the SARS-CoV-2 spike protein.\n   - RFdiffusion was used to design C3-symmetric trimers that rigidly hold three binding domains, matching the ACE2 binding sites on the spike protein trimer.\n   - The designs were predicted by AlphaFold2 to assemble as C3-symmetric oligomers and scaffold the SARS-CoV-2 binder interface with high accuracy.\n\n5. **Experimental Success and Validation:**\n   - The RFdiffusion approach achieved a high experimental success rate, identifying binders with nanomolar affinities from a relatively small number of designs.\n   - The high-resolution cryo-EM structure of one of the designs in complex with influenza HA validated the atomic accuracy of RFdiffusion-generated proteins.\n\n6. **Comparison with Rosetta:**\n   - RFdiffusion significantly outperforms Rosetta-based methods in terms of experimental success rates and the ability to generate diverse and accurate protein designs.\n   - The method reduces the need for high-throughput screening, making it more efficient and cost-effective.\n\n7. **Potential for Future Applications:**\n   - RFdiffusion's ability to scaffold functional sites with any desired symmetry opens new avenues for designing metal-coordinating protein assemblies and other complex protein structures.\n   - The method's flexibility and robustness suggest it could be extended to design nucleic acid binding proteins and protein-ligand interactions, further expanding its applicability in therapeutic and biotechnological contexts.\n\nIn summary, RFdiffusion represents a transformative approach in protein design, offering a more efficient and versatile alternative to traditional Rosetta methods. Its application in designing SARS-CoV-2 nanobody binders highlights its potential to address complex design challenges with high precision and success rates."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational design of nanomolar-binding antibodies specific to multiple SARS-CoV-2 variants by engineering a specificity switch of antibody 80R using RosettaAntibodyDesign (RAbD) results in potential generalizable therapeutic antibodies for novel SARS-CoV-2 virus\" presents a computational approach to design antibodies that can bind with high affinity to multiple variants of the SARS-CoV-2 spike protein. The study leverages the RosettaAntibodyDesign (RAbD) protocol to achieve this goal. Here are the key insights related to the use of Rosetta in designing SARS-CoV-2 nanobody binders:\n\n### RosettaAntibodyDesign (RAbD) Overview:\n1. **Purpose and Approach**: RAbD is used to computationally redesign antibodies to improve their binding affinity and specificity for target antigens. In this study, the authors used RAbD to re-engineer the 80R antibody, which originally binds to SARS-CoV-1, to bind with high affinity to the SARS-CoV-2 spike protein.\n\n2. **Template Selection**: The 80R antibody was chosen as a template because it has a known crystal structure when bound to SARS-CoV-1, but it does not bind to SARS-CoV-2. This makes it an ideal candidate for demonstrating a specificity switch using computational design.\n\n3. **Design Workflow**: The workflow involves:\n   - Identifying antibody-antigen co-crystal structures with structural and sequence homology between SARS-CoV-1 and SARS-CoV-2.\n   - Using RAbD to design variants of the 80R antibody to bind SARS-CoV-2.\n   - Experimentally validating the designed antibodies for binding affinity.\n\n4. **Computational Process**: \n   - The RAbD protocol generated 4000 antibody designs using the 80R structure aligned to SARS-CoV-2.\n   - Different score functions and design options were employed to create a variety of designs.\n   - The designs were filtered and ranked based on predicted binding free energy and total energy scores.\n\n5. **Design Strategies**: \n   - Sequence design was allowed for specific regions (CDR loops) of the antibody.\n   - A designated CDR H3 design run was conducted, allowing mutations sampled from a database of CDR sequences with similar conformations.\n\n6. **Scoring and Selection**: \n   - Designs were ranked based on predicted binding energy and total energy.\n   - Manual inspection was used to identify favorable interactions at the antibody-antigen interface, such as hydrogen bonds and hydrophobic interactions.\n\n7. **Experimental Validation**: \n   - A subset of 30 antibody variants was expressed and purified for experimental testing.\n   - Binding affinities were measured using Biolayer Interferometry (BLI) and ELISA assays.\n\n8. **Results**: \n   - Of the 30 variants, 10 showed measurable binding to the SARS-CoV-2 spike protein, with KD values ranging from 0.468 nM to 114 nM.\n   - The variant 80R_5 demonstrated broad binding to multiple SARS-CoV-2 variants, including Omicron, Delta, Wuhan, and South African variants.\n\n### Insights and Implications:\n- **Rapid Design and Adaptability**: The RAbD-driven approach allows for rapid design and adaptation of antibodies to target new viral strains as they emerge, addressing the challenge of evolving SARS-CoV-2 variants.\n- **Cost and Speed**: Computational redesign offers advantages in terms of speed and cost compared to traditional methods of antibody discovery.\n- **Potential for Therapeutics**: The designed antibodies, particularly 80R_5, show potential as generalizable therapeutics that can bind to diverse SARS-CoV-2 variants.\n- **Limitations**: The approach focuses on increasing binding affinity, which may not directly translate to increased neutralization capability. Further experimental validation is necessary to confirm therapeutic efficacy.\n\nIn summary, the study demonstrates the utility of RosettaAntibodyDesign in the computational redesign of antibodies to target SARS-CoV-2, highlighting its potential to contribute to the rapid development of therapeutic antibodies against emerging viral pathogens."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Atomically accurate de novo design of single-domain antibodies\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Atomically accurate de novo design of single-domain antibodies\" presents a novel approach to designing antibodies using computational methods, specifically focusing on the use of RFdiffusion and RoseTTAFold2 networks. The study addresses the limitations of traditional antibody discovery methods, which are labor-intensive and rely on animal immunization or library screening. Instead, the authors propose a computational pipeline that allows for the de novo design of antibody variable heavy chains (VHHs) targeting specific epitopes.\n\n### Key Insights on \"Rosetta\" in Relation to Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta and Computational Antibody Design**:\n   - Rosetta has historically been used for computational design by grafting residues into existing antibody structures and optimizing interacting regions. However, these methods have limitations in de novo design, particularly for antibodies.\n   - The study leverages Rosetta's capabilities in sequence design to improve the interacting regions of antibodies, but extends beyond by integrating RFdiffusion and RoseTTAFold2 for more comprehensive de novo design.\n\n2. **RFdiffusion and RoseTTAFold2**:\n   - RFdiffusion, a network trained on the Protein Data Bank (PDB), is adapted to design de novo antibodies by focusing on CDR loops and maintaining the framework structure of a user-specified therapeutic antibody.\n   - RoseTTAFold2 is fine-tuned for antibody structure prediction, enhancing its ability to model CDR loops and antibody-antigen interactions accurately.\n\n3. **Designing SARS-CoV-2 Nanobody Binders**:\n   - The study includes the design of VHHs targeting the SARS-CoV-2 receptor binding domain (RBD), demonstrating the potential of RFdiffusion in addressing urgent therapeutic needs.\n   - The designed VHHs are screened using high-throughput methods, such as yeast surface display, to identify candidates with high affinity and specificity for the SARS-CoV-2 RBD.\n\n4. **Validation and Filtering**:\n   - The designed antibodies are validated using cryo-EM, confirming that the structures closely match the computational models.\n   - RoseTTAFold2 is used as a filter to predict the binding mode and structure of designed antibodies, enhancing the likelihood of experimental success.\n\n5. **Challenges and Future Directions**:\n   - The study acknowledges the modest binding affinities of the designed VHHs and the need for further optimization.\n   - Future improvements could involve integrating newer generative frameworks and extending the modeling capabilities to include non-protein atoms, such as glycans, which are relevant for SARS-CoV-2 spike protein interactions.\n\n6. **Implications for Antibody Design**:\n   - The approach offers a faster and potentially more cost-effective alternative to traditional antibody discovery methods.\n   - By focusing on structure-based design, the method allows for the optimization of pharmaceutical properties and the targeting of specific conformational states of antigens.\n\nIn summary, the paper demonstrates the potential of RFdiffusion and RoseTTAFold2 in revolutionizing antibody design, particularly for challenging targets like the SARS-CoV-2 spike protein. The integration of Rosetta's sequence design capabilities with advanced machine learning models paves the way for more efficient and precise antibody development."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"The hinge-engineered IgG1-IgG3 hybrid subclass IgGh47 potently enhances Fc-mediated function of anti-streptococcal and SARS-CoV-2 antibodies\" explores the engineering of antibodies to enhance their function against pathogens like Streptococcus pyogenes and SARS-CoV-2. The study focuses on modifying the hinge region of antibodies to improve their flexibility and, consequently, their ability to mediate immune responses.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta and Structural Modeling**:\n   - The study utilized Rosetta, a computational modeling software, to refine and relax the structures of antibodies and their interactions with antigens. This was crucial in understanding how modifications in the hinge region affect the overall flexibility and binding dynamics of the antibodies.\n   - Rosetta was employed to model the Fc and Fab domains of IgG1 and IgG3 separately, ensuring accurate structural predictions that consider the homo-oligomer state of 1:1. The models were then relaxed using Rosetta's relax protocol, which adjusts side chains and disulfide bridges for optimal stability.\n\n2. **Hinge Region Engineering**:\n   - The paper highlights the importance of the hinge region in antibodies, particularly IgG3, which has an extended hinge allowing for greater flexibility. This flexibility is hypothesized to enhance the antibody's ability to engage with immune cells and mediate effector functions.\n   - By using Rosetta, the researchers were able to model and simulate the effects of different hinge lengths on antibody function, leading to the development of the IgGh47 hybrid, which combines the flexibility of IgG3 with the binding affinity of IgG1.\n\n3. **Molecular Dynamics Simulations**:\n   - Molecular dynamics (MD) simulations, supported by Rosetta models, were crucial in analyzing the flexibility and movement of the Fc domain relative to the antigen. These simulations provided insights into how the engineered hinge affects the spatial orientation and interaction dynamics of the antibody.\n   - The study found that the IgG3 and IgGh62 systems, modeled using Rosetta, exhibited larger degrees of freedom and flexibility compared to IgG1, suggesting that the hinge-engineered antibodies could explore a broader range of conformations to enhance immune engagement.\n\n4. **Implications for Nanobody Design**:\n   - The insights gained from Rosetta modeling and MD simulations can be applied to the design of nanobodies, which are smaller antibody fragments with potential therapeutic applications. By understanding the structural dynamics conferred by hinge modifications, researchers can design nanobodies with optimized flexibility and binding properties for targeting SARS-CoV-2.\n   - The study's approach to hinge engineering provides a framework for enhancing the functional capabilities of nanobodies, potentially leading to more effective treatments for viral infections like COVID-19.\n\nIn summary, the use of Rosetta in this study was pivotal for modeling the structural effects of hinge modifications in antibodies, providing a deeper understanding of how these changes can enhance immune function. This knowledge is directly applicable to the design of nanobodies for targeting SARS-CoV-2, offering a promising avenue for developing advanced therapeutic agents."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Structure-based dual affinity optimization of a SARS-CoV-1/2 cross-reactive single-domain antibody\" presents a comprehensive study on the optimization of the VHH-72 single-domain antibody to enhance its binding affinity to the SARS-CoV-2 spike protein while retaining its affinity for the SARS-CoV-1 spike protein. The study employs a structure-based approach using the ADAPT platform, which integrates computational predictions with experimental validation to achieve dual-affinity optimization.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Role of Rosetta in Computational Design**:\n   - Rosetta is one of the three computational protocols used in the ADAPT platform for evaluating the energies of single-point mutations. It is employed alongside SIE-SCWRL and FoldX to build structures and score the binding affinities of VHH-72 mutants.\n   - The consensus approach combines results from Rosetta, SIE, and FoldX to predict the most promising mutations for experimental testing. This method helps in identifying mutations that could potentially improve binding affinity to the SARS-CoV-2 spike protein.\n\n2. **Mutation Scanning and Scoring**:\n   - Rosetta-Interface is specifically used to score the binding affinity of VHH-72 mutants. The scoring is based on the average Z-score and rank score over the energy functions from the three protocols.\n   - The consensus scoring approach, which includes Rosetta, helps in filtering out mutations that are predicted to destabilize the VHH structure or negatively impact binding affinity.\n\n3. **Structural Insights and Predictions**:\n   - Rosetta contributes to the structural modeling and prediction of how mutations might affect the binding interface between VHH-72 and the SARS-CoV-2 spike protein.\n   - The computational predictions, including those from Rosetta, guide the selection of mutations that introduce new interactions or enhance existing ones at the binding interface, thereby improving binding affinity.\n\n4. **False-Positive Predictions**:\n   - The study acknowledges the occurrence of false-positive predictions, where some mutations predicted to improve binding did not perform as expected experimentally. Rosetta, as part of the consensus approach, plays a role in these predictions.\n   - The analysis of false positives highlights the challenges in accurately predicting the balance between new non-polar contacts and steric strain, as well as the balance between electrostatic interactions and solvation effects.\n\n5. **Impact on Binding Affinity and Neutralization**:\n   - The use of Rosetta in the computational design process contributes to the identification of mutations that significantly improve the binding affinity of VHH-72 to the SARS-CoV-2 spike protein.\n   - The optimized VHH-72 mutants, guided by Rosetta and other computational tools, demonstrate enhanced virus neutralization capabilities in vitro and in vivo, underscoring the effectiveness of the structure-based design approach.\n\nIn summary, Rosetta plays a crucial role in the computational design and optimization of VHH-72 nanobody binders for SARS-CoV-2. It is part of a consensus approach that integrates multiple computational tools to predict and evaluate mutations, ultimately guiding the development of nanobodies with improved binding affinity and neutralization efficacy against SARS-CoV-2."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design\" provides a comprehensive overview of the Rosetta software suite's capabilities in antibody and antigen modeling, with a particular focus on its application to designing SARS-CoV-2 nanobody binders. Here are the key insights related to Rosetta's role in this context:\n\n### Rosetta Software Suite\n- **Rosetta Overview**: Rosetta is a versatile software suite for biomolecular modeling, maintained by RosettaCommons, comprising over 70 academic research groups. It supports protein structure prediction, ligand docking, homology modeling, protein design, and RNA structure prediction.\n- **Energy Function**: Rosetta employs a Metropolis Monte Carlo sampling strategy guided by an energy function, which is a weighted sum of physics-based and statistically derived potentials. The default energy function, ref2015, is optimized for various use cases, including membrane proteins and noncanonical amino acids.\n\n### Antibody and Antigen Design\n- **Antibody Structure Prediction**: Rosetta provides several protocols for antibody modeling, such as RosettaAntibody, AbPredict, and RosettaCM. These protocols leverage the conserved immunoglobulin fold and the availability of numerous homology templates for accurate modeling.\n- **CDR Loop Modeling**: Accurate prediction of the complementary-determining regions (CDRs), especially HCDR3, is crucial for antibody design. RosettaAntibody uses a combination of template selection, loop grafting, and de novo loop modeling to achieve this.\n- **Nanobody Design**: Camelid VHH nanobodies, which lack a light chain, are modeled with specific considerations in RosettaAntibody. These include additional refinement of HCDR1 and modeling of disulfide bonds between HCDR1 and HCDR3.\n\n### Docking and Design\n- **Antibody-Antigen Docking**: RosettaDock and its extension SnugDock are used for docking antibody-antigen complexes. SnugDock refines CDR loops and VH\u2013VL orientations, making it suitable for homology model-derived antibodies.\n- **Antibody Design**: RosettaAntibodyDesign (RAbD) and AbDesign are protocols for optimizing antibody sequences to improve affinity and specificity. RAbD allows for both sequence and graft design based on canonical clusters.\n\n### Epitope-Focused Design\n- **Immunogen Design**: Rosetta supports epitope-focused immunogen design, which involves grafting epitopes onto scaffold proteins to elicit targeted immune responses. This approach is crucial for designing vaccines against challenging targets like HIV and influenza.\n- **Glycan Modeling**: The RosettaCarbohydrate framework enables modeling and design of glycosylated proteins, which is important for understanding viral glycoproteins like the SARS-CoV-2 spike protein.\n\n### Application to SARS-CoV-2\n- **Nanobody Binders**: The protocols and methodologies described in the paper are directly applicable to designing nanobody binders for the SARS-CoV-2 spike protein. The ability to model and design antibodies with high specificity and affinity is critical for developing therapeutic and diagnostic tools against COVID-19.\n\nOverall, Rosetta provides a robust platform for antibody and antigen design, with specific applications to SARS-CoV-2 nanobody binders. Its comprehensive suite of tools allows for detailed modeling, docking, and design, facilitating the development of novel therapeutics and vaccines."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"MHCEpitopeEnergy, a flexible Rosetta-based biotherapeutic deimmunization platform\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"MHCEpitopeEnergy, a flexible Rosetta-based biotherapeutic deimmunization platform\" presents a novel approach to deimmunizing protein therapeutics using the Rosetta protein design suite. This approach integrates epitope prediction methods into Rosetta, allowing for the design of protein variants that are less likely to trigger an immune response while maintaining their therapeutic function. Here are the key insights related to the use of Rosetta in designing SARS-CoV-2 nanobody binders and other biotherapeutics:\n\n### Rosetta's Role in Protein Design:\n1. **Monte Carlo-Based Design**: Rosetta uses a Monte Carlo-based module called the \"packer\" to optimize amino acid sequences and side-chain conformations. This process minimizes an objective function, typically the Rosetta energy function, which is a weighted sum of scoring terms.\n\n2. **Integration of Epitope Prediction**: The paper introduces a new scoring term, \"mhc_epitope,\" into Rosetta, allowing for the incorporation of epitope prediction into the design process. This term enables multi-objective optimization, where deimmunization is considered alongside other design goals.\n\n3. **Modular and Flexible**: The integration of mhc_epitope is modular, allowing it to work with various epitope predictors. This flexibility means that new predictors can be easily added, and the approach can be adapted for different design contexts, including the design of SARS-CoV-2 nanobody binders.\n\n4. **Efficient Scoring and Design**: The mhc_epitope scoring term evaluates the immunogenicity of peptides within a protein sequence. It updates scores efficiently during design simulations, ensuring that only relevant peptides are re-scored when sequence changes occur.\n\n5. **Compatibility with Diverse Structures**: The scoring term is compatible with symmetric structures, non-protein residues, and proteins containing non-canonical amino acids, making it versatile for various protein design tasks.\n\n### Application to SARS-CoV-2 Nanobody Binders:\n1. **Deimmunization of Therapeutics**: The platform can be used to design nanobody binders for SARS-CoV-2 that are less likely to elicit an immune response. This is crucial for developing safe and effective therapeutics.\n\n2. **Targeted Deimmunization**: The Rosetta framework allows for targeted deimmunization of specific regions within a protein, such as the binding interface of a nanobody with the SARS-CoV-2 spike protein.\n\n3. **Predictor Integration**: By integrating state-of-the-art epitope predictors like NetMHCII, the platform can accurately predict and mitigate potential immunogenic hotspots in nanobody designs.\n\n4. **Benchmarking and Validation**: The paper demonstrates the effectiveness of the mhc_epitope scoring term through benchmarking on diverse protein sets, suggesting its utility in designing deimmunized nanobody binders.\n\n5. **Design Flexibility**: Users can customize design protocols to balance deimmunization with other design objectives, such as maintaining binding affinity and stability, which are critical for nanobody efficacy.\n\n### Conclusion:\nThe integration of MHCEpitopeEnergy into Rosetta represents a significant advancement in the computational design of deimmunized protein therapeutics. For SARS-CoV-2 nanobody binders, this approach offers a powerful tool to design candidates that are both effective and safe, minimizing the risk of adverse immune responses. The flexibility and modularity of the platform ensure that it can adapt to evolving design challenges and incorporate new predictive insights as they become available."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"RosettaSurf\u2014A surface-centric computational design approach\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"RosettaSurf\u2014A surface-centric computational design approach\" introduces a novel protocol within the Rosetta software suite, focusing on the design of proteins by optimizing their molecular surface features, specifically shape and electrostatic properties. This approach diverges from traditional protein design methods that primarily rely on energy-based scoring functions to predict amino acid sequences that stabilize a given protein structure. Instead, RosettaSurf emphasizes the importance of protein surfaces, which are critical for molecular interactions and function.\n\n### Key Insights on Rosetta and SARS-CoV-2 Nanobody Design:\n\n1. **Surface-Centric Design Philosophy**:\n   - RosettaSurf operates on the premise that protein surfaces, which dictate interaction capabilities, can be optimized independently of the underlying sequence and backbone. This allows for the design of proteins with desired functional surfaces even in the absence of structurally similar templates.\n\n2. **Molecular Surface Representation**:\n   - Proteins are represented as near-continuous surfaces, capturing geometric and electrostatic features. This representation facilitates the comparison of protein surfaces to identify functional similarities, which is crucial for designing proteins that can mimic specific binding sites.\n\n3. **Surface Similarity Scoring (SurfS)**:\n   - The SurfS score combines shape and electrostatic similarity to evaluate how closely a designed protein surface matches a target surface. This scoring system is integral to RosettaSurf's ability to guide the design process towards functional protein interfaces.\n\n4. **Application to SARS-CoV-2 Nanobody Design**:\n   - While the paper does not specifically focus on SARS-CoV-2, the principles of RosettaSurf can be applied to design nanobodies targeting the SARS-CoV-2 spike protein. By optimizing the surface features of nanobodies, RosettaSurf can potentially enhance their binding affinity and specificity to viral epitopes, aiding in the development of therapeutic agents.\n\n5. **Benchmarking and Validation**:\n   - RosettaSurf was benchmarked against traditional design methods, demonstrating superior performance in recovering native amino acid sequences at protein interfaces. This suggests its potential effectiveness in designing nanobodies with high specificity for viral targets like SARS-CoV-2.\n\n6. **Potential for Immunogen Design**:\n   - The protocol's ability to design proteins that mimic antigenic sites makes it a promising tool for vaccine development. By presenting viral epitopes on designed scaffolds, RosettaSurf could facilitate the creation of immunogens that elicit targeted immune responses.\n\n7. **Integration with Rosetta Framework**:\n   - RosettaSurf is implemented within the RosettaScripts environment, allowing seamless integration with existing Rosetta protocols. This modularity enables the combination of surface-centric design with other computational techniques, such as molecular dynamics simulations, to refine and validate nanobody designs.\n\n8. **Future Directions**:\n   - The paper suggests potential applications in designing proteins with novel functions, including therapeutic nanobodies. The exploration of \"surface degeneracy,\" where similar surface features can be achieved with different amino acid sequences, could lead to innovative approaches in protein engineering.\n\nIn summary, RosettaSurf represents a significant advancement in computational protein design, emphasizing the optimization of molecular surfaces to achieve desired functional properties. Its application to nanobody design against targets like the SARS-CoV-2 spike protein holds promise for developing effective therapeutic and diagnostic tools."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Rosetta:MSF:NN: Boosting performance of multi-state computational protein design with a neural network\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Rosetta:MSF:NN: Boosting performance of multi-state computational protein design with a neural network\" presents a novel approach to computational protein design by integrating neural networks (NNs) into the Rosetta multi-state design (MSD) framework. This integration aims to enhance the efficiency and effectiveness of protein design, particularly in complex scenarios requiring the modeling of multiple conformational states. Here is a detailed summary focusing on the key insights about Rosetta in relation to designing SARS-CoV-2 nanobody binders:\n\n### Overview of Rosetta and Multi-State Design (MSD)\n- **Rosetta Software Suite**: A highly flexible tool for protein design, capable of addressing diverse design challenges such as increasing thermostability, altering ligand binding, and redesigning protein interactions.\n- **Multi-State Design (MSD)**: An advanced protocol within Rosetta that evaluates a single sequence across multiple conformational states, offering a more precise approach than single-state design (SSD) for problems involving structural flexibility.\n\n### Challenges and Innovations\n- **Computational Demands**: MSD protocols are computationally intensive as they require scoring each candidate sequence across multiple states, leading to high computational costs.\n- **Neural Network Integration**: The paper introduces Rosetta:MSF:NN, which replaces the genetic algorithm with a neural network to reduce computational costs while maintaining or improving design quality.\n\n### Neural Network Approach\n- **Training and Prediction**: The NN is trained using a moderate number of 3D models to learn the energy landscape of a specific design problem. It predicts scores for a large number of candidate sequences, allowing for extensive sequence space exploration.\n- **Iterative Process**: The NN is retrained iteratively with updated candidate sequences, improving its predictive accuracy over time.\n\n### Performance and Efficiency\n- **Speed and Accuracy**: Rosetta:MSF:NN converges approximately ten times faster than the genetic algorithm-based approach, finding sequences with comparable or better scores.\n- **Extensive Sampling**: The NN-based approach allows for the assessment of millions of candidate sequences per iteration, significantly broadening the search space compared to traditional methods.\n\n### Application to SARS-CoV-2 Nanobody Design\n- **Structural Flexibility**: Designing nanobodies against the SARS-CoV-2 spike protein requires accounting for the protein's conformational changes. MSD protocols, enhanced by NNs, are particularly suited for this task.\n- **Potential for Rapid Development**: The accelerated convergence and extensive sampling capabilities of Rosetta:MSF:NN can facilitate the rapid identification of high-affinity nanobody candidates, crucial for timely therapeutic development.\n\n### Insights and Implications\n- **Energy Landscape Learning**: The NN effectively learns the complex energy landscape of protein design problems, even with limited initial data, making it a powerful tool for exploring diverse sequence possibilities.\n- **Broader Applicability**: While the study focuses on enzyme redesign and ligand-binding problems, the principles and methods are applicable to antibody and nanobody design, including those targeting viral proteins like SARS-CoV-2.\n\n### Conclusion\nThe integration of neural networks into the Rosetta MSD framework represents a significant advancement in computational protein design. By enhancing the speed and breadth of sequence exploration, Rosetta:MSF:NN offers a promising approach for designing nanobodies and other therapeutic proteins, particularly in response to emerging viral threats such as SARS-CoV-2. This approach not only improves efficiency but also opens new avenues for exploring alternative regions of sequence space, potentially leading to novel and effective therapeutic candidates."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Structural modeling of antibody variable regions using deep learning\u2014progress and perspectives on drug discovery\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Structural modeling of antibody variable regions using deep learning\u2014progress and perspectives on drug discovery\" provides a comprehensive overview of recent advances in antibody structure prediction, emphasizing the role of deep learning in enhancing drug discovery processes. A significant focus is on the application of these methods to design SARS-CoV-2 nanobody binders, with particular attention to the Rosetta software suite.\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Role of Rosetta in Antibody Modeling:**\n   - Rosetta is a critical tool in the structural modeling of antibodies, particularly in refining structures predicted by deep learning models. It is used to reconstruct full structures from predicted inter-residue distances and orientation angles, as seen in methods like DeepH3 and DeepAb.\n\n2. **Integration with Deep Learning Models:**\n   - Deep learning models such as DeepH3 and DeepAb utilize Rosetta for structure realization. These models predict discretized inter-residue distances and orientation angles, which Rosetta then uses to generate accurate 3D structures. This integration enhances the precision of antibody modeling, crucial for designing effective binders against targets like the SARS-CoV-2 spike protein.\n\n3. **Refinement of Predicted Structures:**\n   - Rosetta plays a pivotal role in refining antibody structures to reduce physical clashes and improve the overall quality. This refinement is essential for ensuring that the predicted structures are not only accurate but also physically plausible, which is vital for practical applications in drug discovery.\n\n4. **Application in CDR-H3 Loop Prediction:**\n   - The CDR-H3 loop is a critical region for antibody binding, and its accurate prediction is challenging due to its variability. Rosetta aids in refining the CDR-H3 loop structures predicted by models like DeepH3, thereby improving the accuracy of these predictions, which is crucial for designing nanobodies that can effectively bind to the SARS-CoV-2 spike protein.\n\n5. **Use in Virtual Screening and De Novo Design:**\n   - Rosetta's ability to refine structures makes it a valuable tool in virtual screening processes, where millions of antibody structures are modeled and assessed for their binding potential to specific targets. This capability is particularly relevant for the de novo design of antibodies against SARS-CoV-2, where the goal is to computationally define sequences that can bind to the virus's spike protein.\n\n6. **Enhancing Structural Predictions for Drug Discovery:**\n   - By integrating with deep learning models, Rosetta enhances the structural predictions of antibodies, making them more suitable for drug discovery applications. This integration allows for the generation of high-quality models that can be used in various stages of the drug discovery pipeline, from lead optimization to epitope and paratope prediction.\n\nIn summary, Rosetta is a crucial component in the structural modeling of antibodies, particularly in the context of designing SARS-CoV-2 nanobody binders. Its integration with deep learning models enhances the accuracy and physical plausibility of predicted structures, facilitating their use in drug discovery processes. This synergy between Rosetta and deep learning models represents a significant advancement in the field, offering promising avenues for the development of effective therapeutics against challenging targets like the SARS-CoV-2 spike protein."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Role of backbone strain in de novo design of complex \u03b1/\u03b2 protein structures\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Role of backbone strain in de novo design of complex \u03b1/\u03b2 protein structures\" explores the principles of protein design, focusing on the importance of considering global backbone strain in the design of larger \u03b1\u03b2-proteins. The study builds on previous work that established principles for designing ideal proteins with consistent local and non-local interactions, enabling the creation of new \u03b1\u03b2-proteins with up to four \u03b2-strands. This research extends those principles to design larger proteins with five- and six-stranded \u03b2-sheets flanked by \u03b1-helices.\n\n### Key Insights on Rosetta in Protein Design:\n\n1. **Rosetta's Role in Protein Design**:\n   - Rosetta is a computational tool used extensively in this study for sequence-independent folding simulations and full-atom sequence design calculations. It helps generate backbone structures and build side chains on these structures, selecting designs with low energy, tight side chain packing, and high compatibility between local sequence and structure.\n\n2. **Design Process Using Rosetta**:\n   - The design process involves several steps using Rosetta:\n     - **Backbone Building**: Rosetta sequence-independent folding simulations are used to generate rough backbone structures with target topologies.\n     - **Sequence Design**: Rosetta full-atom sequence design calculations are performed to build side chains, aiming for funneled energy landscapes that lead to the designed structure.\n     - **Energy Landscape Mapping**: Rosetta de novo folding simulations map the energy landscapes of the designs to ensure they funnel into the desired structure.\n\n3. **Challenges and Solutions**:\n   - Initial designs showed strand swapping in \u03b2-sheets, indicating a need to incorporate global backbone strain considerations. The Rosetta energy calculations initially failed to predict this strand-swapped topology as the lowest energy state, highlighting limitations in the energy function.\n   - By incorporating global backbone strain into the design methodology, the researchers successfully designed proteins with the intended unswapped strand arrangements.\n\n4. **Experimental Validation**:\n   - Experimental techniques such as NMR spectroscopy were used to validate the computational models. The NMR structures of some designs showed strand swapping, prompting further investigation into backbone strain.\n   - The study emphasizes the importance of experimental structure determination in guiding the improvement of de novo design methodologies.\n\n5. **Implications for SARS-CoV-2 Nanobody Design**:\n   - While the paper does not directly address SARS-CoV-2 nanobody design, the insights gained from understanding backbone strain and protein topology can inform the design of nanobodies targeting the SARS-CoV-2 spike protein.\n   - Rosetta's capabilities in modeling protein interactions and designing stable protein structures can be leveraged to identify potential nanobody candidates that effectively bind to the spike protein, considering both local and global structural dynamics.\n\nIn summary, the paper highlights the critical role of considering global backbone strain in protein design and the utility of Rosetta in modeling and optimizing protein structures. These insights are valuable for designing complex proteins, including potential therapeutic nanobodies for SARS-CoV-2."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6 specific nanobody restricts M. tuberculosis growth in macrophages\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6 specific nanobody restricts M. tuberculosis growth in macrophages\" explores the role of the ESAT-6 protein in Mycobacterium tuberculosis (Mtb) pathogenesis and its interaction with the CFP-10 protein. The study focuses on understanding the biochemical properties of ESAT-6, its self-association behavior under different pH conditions, and the development of a specific nanobody to inhibit Mtb growth.\n\n### Key Insights on \"Rosetta\" in Relation to Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Protein Modeling and Molecular Dynamics:**\n   - The study employs molecular dynamics simulations to model the interaction interfaces of ESAT-6, particularly under acidic conditions where it forms tetramers. This approach is crucial for understanding protein-protein interactions and can be applied to SARS-CoV-2 research.\n   - For SARS-CoV-2, similar modeling techniques can be used to predict the binding sites and conformational changes of the spike protein, aiding in the design of nanobodies that can effectively neutralize the virus.\n\n2. **Nanobody Design and Characterization:**\n   - The paper describes the generation of an alpaca-derived nanobody (E11rv) that specifically binds to ESAT-6, inhibiting Mtb growth. This highlights the potential of nanobodies as therapeutic agents.\n   - In the context of SARS-CoV-2, nanobodies can be designed to target specific epitopes on the spike protein using similar phage display techniques and structural insights gained from modeling.\n\n3. **Biochemical and Biophysical Techniques:**\n   - Techniques such as biolayer interferometry (BLI) and hydrogen-deuterium exchange mass spectrometry (HDX-MS) are used to characterize the binding kinetics and interaction sites of the nanobody with ESAT-6.\n   - These techniques can be adapted to study the interaction of nanobodies with the SARS-CoV-2 spike protein, providing detailed insights into binding affinities and structural dynamics.\n\n4. **Structural Dynamics and Stability:**\n   - The study reveals that ESAT-6 forms stable dimers at neutral pH and tetramers at acidic pH, with molecular dynamics simulations providing insights into these conformational states.\n   - Understanding the structural dynamics of the SARS-CoV-2 spike protein, particularly under different environmental conditions, is crucial for designing stable and effective nanobody binders.\n\n5. **Application of Rosetta in Protein Design:**\n   - While the paper does not explicitly mention the use of Rosetta, the principles of protein modeling and simulation align with Rosetta's capabilities in predicting protein structures and designing protein-protein interactions.\n   - For SARS-CoV-2, Rosetta can be employed to design nanobodies with high specificity and affinity for the spike protein, leveraging its algorithms for protein folding and docking.\n\nIn summary, the methodologies and insights from the study on ESAT-6 and its nanobody can be directly applied to the design and characterization of nanobodies targeting the SARS-CoV-2 spike protein. The use of molecular dynamics, protein modeling, and advanced biophysical techniques are critical in developing effective therapeutic agents against viral pathogens."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants\" presents a comprehensive study on the development of a broadly neutralizing antibody (nAb) against SARS-CoV-2 and its variants. The study focuses on the use of computational tools, particularly the Rosetta software suite, to design and optimize antibodies that can effectively bind to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein across various variants.\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Initial Antibody Design Using Rosetta:**\n   - The study utilized Rosetta to perform sequence design on the complementarity-determining regions (CDRs) of antibodies. This involved using a Monte Carlo search to explore amino acid sequences that could potentially bind to the SARS-CoV-2 RBD.\n   - Four pseudo-complexes were constructed by aligning the SARS-CoV-2 RBD with known structures of human antibodies bound to the SARS-CoV-1 RBD. These complexes were refined using the Rosetta FastRelax protocol.\n\n2. **Sequence Design Protocol:**\n   - The sequence design protocol in Rosetta allowed for changes in CDR residues within 7 \u00c5 of the RBD, while residues within 7\u20139 \u00c5 were restricted to repacking. This approach aimed to optimize interactions at the antibody-antigen interface.\n   - Water molecules were incorporated at the Fv-RBD interface using ExplicitWaterMover to account for buried unsatisfied polar atoms, which is crucial for accurate modeling of binding interactions.\n\n3. **Selection of Antibody Designs:**\n   - From approximately 1000 design models, 55 were selected based on criteria such as shape complementarity, buried solvent-accessible surface area, and the number of unsatisfied polar atoms. This selection process was critical in identifying promising candidates for further experimental validation.\n\n4. **Experimental Validation and Affinity Enhancement:**\n   - The lead antibody, D27, was identified through biolayer interferometry (BLI) experiments, although its initial binding affinity was weaker than desired. The crystal structure of D27 bound to the SARS-CoV-2 RBD validated the design accuracy.\n   - Subsequent affinity enhancement involved extending the CDR loops and using yeast surface display to select variants with improved binding affinity. This iterative process of computational design followed by experimental validation and optimization exemplifies the synergy between in silico and in vitro approaches.\n\n5. **Computational Affinity Maturation:**\n   - Rosetta was used for computational affinity maturation, particularly to address mutations such as N501Y found in variants like Alpha. This involved targeted sequence design to optimize local interactions and enhance binding affinity.\n   - The study demonstrated that computational methods could rapidly adapt antibodies to emerging variants, achieving significant improvements in binding affinity.\n\n6. **Broad Neutralization Potential:**\n   - The final antibody, D27LEY, exhibited ultra-potent binding affinity for various SARS-CoV-2 variants and cross-reactivity with SARS-CoV-1 and pangolin coronavirus RBDs. This broad neutralization potential underscores the effectiveness of the computational design strategy.\n\n7. **Implications for Vaccine and Therapeutic Development:**\n   - The study highlights a vulnerable target site on the RBD that can be exploited for developing broadly neutralizing antibodies and vaccines. The computational approach using Rosetta provides a framework for designing antibodies with high specificity and affinity, which is crucial for addressing antigenic drift in viral pathogens.\n\nIn summary, the use of Rosetta in this study was pivotal in the computational design and optimization of a neutralizing antibody with broad efficacy against SARS-CoV-2 variants. The integration of computational modeling with experimental validation and affinity maturation showcases a powerful strategy for developing next-generation therapeutics and vaccines."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational redesign of Beta-27 Fab with substantially better predicted binding affinity to the SARS-CoV-2 Omicron variant than human ACE2 receptor\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational redesign of Beta-27 Fab with substantially better predicted binding affinity to the SARS-CoV-2 Omicron variant than human ACE2 receptor\" focuses on enhancing the binding affinity of the Beta-27 Fab antibody fragment to the SARS-CoV-2 Omicron variant using computational protein design and molecular dynamics simulations. A key aspect of this study is the use of the Rosetta software suite, specifically the RosettaAntibodyDesign (RAbD) module, to redesign the complementarity-determining regions (CDRs) of the Beta-27 Fab to improve its binding affinity to the Omicron variant's receptor-binding domain (RBD).\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **RosettaAntibodyDesign (RAbD) Utilization**:\n   - The study employed RAbD, a module within Rosetta, to redesign the CDRs of the Beta-27 Fab. This involved allowing each residue within the CDRs to be any of the standard amino acids, optimizing for sequences that enhance binding affinity to the Omicron RBD.\n   - RAbD uses a Monte Carlo-based approach to explore sequence and structural space, generating a large number of potential designs and evaluating them based on predicted binding free energy.\n\n2. **Design Process**:\n   - The redesign focused on all six CDRs (H1, H2, H3, L1, L2, and L3) of the Beta-27 Fab. The goal was to achieve a binding affinity to the Omicron RBD that surpasses both the original Beta-27 Fab and the human ACE2 receptor.\n   - The study generated 500 independent runs, producing 500 conformations of designed sequences. The top ten designs with the best binding free energy (\u0394Gbind) values, as calculated by Rosetta, were selected for further validation through molecular dynamics simulations.\n\n3. **Validation and Analysis**:\n   - The selected designs underwent molecular dynamics simulations to validate their stability and binding affinity using the MM-GBSA method, which provides a more accurate prediction of binding free energies.\n   - The study identified five redesigned Fabs (Beta-27-D01, Beta-27-D03, Beta-27-D06, Beta-27-D09, and Beta-27-D10) with significantly improved binding affinities compared to the original Beta-27 Fab and ACE2.\n\n4. **Binding Affinity Improvements**:\n   - The enhanced binding affinities were primarily attributed to increased interactions in the light chain CDRs, particularly L2 and L3. These regions were identified as promising targets for further optimization.\n   - The best-designed Fab, Beta-27-D10, showed a binding affinity improvement of approximately 20 kcal/mol over the original Beta-27 Fab and about 33 kcal/mol over ACE2.\n\n5. **Structural Insights**:\n   - The study provided detailed structural insights into the binding interactions, highlighting the importance of specific residues and interactions, such as hydrogen bonds and pi interactions, in enhancing binding affinity.\n   - The redesigned Fabs maintained similar binding poses to the original Fab, suggesting that they could effectively block the interaction between ACE2 and the Omicron RBD.\n\n6. **Implications for Therapeutic Development**:\n   - The findings suggest that computational protein design using Rosetta can effectively enhance antibody binding affinities, offering a promising approach for developing therapeutic antibodies against emerging SARS-CoV-2 variants.\n   - The study emphasizes the potential of using computational tools like Rosetta to rapidly adapt existing antibodies to new viral variants, which is crucial for addressing the ongoing challenges posed by the COVID-19 pandemic.\n\nIn summary, the paper demonstrates the power of Rosetta, particularly the RAbD module, in redesigning antibody fragments to improve their binding affinity to viral targets. This approach not only enhances our understanding of antibody-antigen interactions but also provides a framework for developing effective therapeutics against rapidly evolving pathogens like SARS-CoV-2."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Robustification of RosettaAntibody and Rosetta SnugDock\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Robustification of RosettaAntibody and Rosetta SnugDock\" discusses significant advancements in the RosettaAntibody and Rosetta SnugDock protocols, which are crucial for antibody structure prediction and antibody-antigen docking. These improvements are particularly relevant in the context of designing nanobody binders for SARS-CoV-2, as they enhance the accuracy and robustness of computational models used in drug discovery and therapeutic development.\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Template Database Automation**:\n   - The RosettaAntibody protocol now features an automated template database, which ensures access to the latest antibody structures from SAbDab. This automation increases template coverage and reduces errors, crucial for modeling diverse antibodies, including those targeting SARS-CoV-2.\n\n2. **Modeling of Single-Domain Antibodies (Nanobodies)**:\n   - Both RosettaAntibody and SnugDock have been updated to model heavy-chain-only antibodies (nanobodies) without additional specifications. This is particularly important for SARS-CoV-2, as nanobodies offer a promising therapeutic avenue due to their small size and stability.\n\n3. **Improved Loop Modeling Techniques**:\n   - A new fragment-based loop modeling approach has been introduced, enhancing the sampling of backbone dihedral angles from homologous fragments. This is vital for accurately modeling the diverse CDR-H3 loops, which are critical for antigen binding in SARS-CoV-2 nanobodies.\n\n4. **Enhanced Docking Protocols**:\n   - SnugDock has been updated with a universal FoldTree, allowing for flexible docking of antibody-antigen complexes, including nanobodies. This improvement facilitates the modeling of interactions with the SARS-CoV-2 spike protein, accommodating the induced-fit binding necessary for effective neutralization.\n\n5. **Scientific Benchmarking**:\n   - Rigorous scientific benchmarks have been developed to regularly assess the performance of RosettaAntibody and SnugDock. These benchmarks ensure the protocols' reliability in real-life scenarios, such as predicting the binding of nanobodies to the SARS-CoV-2 spike protein.\n\n6. **Constraints and Filters**:\n   - New constraints, such as the automated Q\u2013Q hydrogen bond constraint, have been implemented to improve model quality. These constraints are crucial for maintaining structural integrity during simulations of nanobody interactions with SARS-CoV-2.\n\n7. **User Interface Simplification**:\n   - The user interface for both protocols has been simplified, making them more accessible for researchers focusing on SARS-CoV-2. This ease of use allows for broader application in virtual screening efforts to identify potential nanobody candidates.\n\n8. **Future Directions**:\n   - The paper highlights ongoing challenges, such as improving CDR-H3 loop modeling and developing a truly universal FoldTree for multi-body docking. Addressing these challenges will further enhance the ability to model complex interactions with the SARS-CoV-2 spike protein.\n\nIn summary, the advancements in RosettaAntibody and SnugDock significantly enhance the ability to predict and model antibody and nanobody structures, particularly in the context of SARS-CoV-2. These improvements facilitate the identification and optimization of potential therapeutic candidates, contributing to the rapid development of effective treatments against COVID-19."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational analysis of affinity dynamics between the variants of SARS-CoV-2 spike protein (RBD) and human ACE-2 receptor\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational analysis of affinity dynamics between the variants of SARS-CoV-2 spike protein (RBD) and human ACE-2 receptor\" employs computational techniques to explore the interactions between the SARS-CoV-2 spike protein's Receptor Binding Domain (RBD) and the human ACE-2 receptor. The study focuses on Variants of Concern (VOCs), including Omicron subvariants, and utilizes protein structure prediction algorithms and molecular docking techniques to assess how mutations in the RBD affect its binding affinity with hACE-2.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **trRosetta for Structure Prediction**:\n   - The study uses the trRosetta algorithm, a deep learning-based method, for de novo prediction of the 3D structures of the RBD from various SARS-CoV-2 variants. This approach is crucial for understanding the structural changes induced by mutations, particularly in the absence of similar structures in public databases.\n   - The trRosetta-generated models were superimposed onto the original Wuhan variant using PyMol, revealing RMSD values between 0.69 to 0.77 \u00c5, indicating a high degree of structural conservation among the variants.\n\n2. **Structural Dynamics and Mutations**:\n   - The analysis highlights that mutations predominantly affect the interaction interface on the RBD's bottom section, with significant structural variations observed in the Receptor-Binding Motif (RBM).\n   - The study identifies specific residues within the RBM that are crucial for binding, providing insights into potential targets for designing nanobody binders.\n\n3. **Binding Affinity and Stability**:\n   - The study employs HADDOCK for docking simulations and PRODIGY for binding affinity predictions. It finds that Omicron subvariants, particularly BA.1.1, exhibit the highest binding affinity to hACE2, surpassing other variants.\n   - The binding stability of hACE2 and RBD complexes follows the order: Omicron BA.1.1 > Omicron BA.5.2.1 > Omicron BA.2.12.1 > Delta > Omicron-B.1.529.1 > Gamma > Alpha > Beta > Original Wuhan strain.\n\n4. **Implications for Nanobody Design**:\n   - The insights gained from trRosetta predictions and docking analyses can guide the design of nanobody binders that specifically target the RBD of SARS-CoV-2 variants.\n   - Understanding the structural dynamics and key interacting residues allows for the rational design of nanobodies that can effectively neutralize the virus by blocking its interaction with hACE2.\n\n5. **Potential for Structure-Based Drug Design**:\n   - The study's methodology forms a comprehensive pipeline for future investigations into COVID-19, offering a valuable approach for developing strategies to combat viral diseases through the design of specific subunit vaccines and therapeutic interventions.\n\nOverall, the use of trRosetta in this study underscores its potential in predicting structural changes and guiding the design of nanobody binders against SARS-CoV-2, particularly in addressing the challenges posed by emerging variants."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Massively parallel protein-protein interaction measurement by sequencing (MP3-seq) enables rapid screening of protein heterodimers\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Massively parallel protein-protein interaction measurement by sequencing (MP3-seq) enables rapid screening of protein heterodimers\" introduces a novel high-throughput method for measuring protein-protein interactions (PPIs) using a yeast-two-hybrid approach combined with sequencing. This method, MP3-seq, allows for the rapid and scalable measurement of PPIs by associating DNA barcodes with specific protein pairs and using sequencing to quantify interaction strength. The study demonstrates the utility of MP3-seq in characterizing interactions among rationally designed heterodimers and exploring specificity elements in coiled-coil interactions.\n\n### Key Insights on \"Rosetta\" in Relation to Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta's Role in Protein Design**:\n   - Rosetta is a computational tool used for predicting and designing protein structures and interactions. In the context of this study, Rosetta is employed to gather physics-based metrics such as interaction energy and interface surface area for simulated dimer complexes. These metrics are crucial for understanding the structural dynamics and interaction strengths of protein complexes.\n\n2. **Integration with AlphaFold-Multimer (AF-M)**:\n   - The study integrates Rosetta with AlphaFold-Multimer (AF-M), a deep learning model for predicting protein structures with multiple chains. AF-M is used to predict coiled heterodimer structures, and its error metrics are combined with Rosetta's physics-based metrics to train models that predict MP3-seq values and classify interactions.\n   - This integration highlights the potential of combining machine learning models like AF-M with traditional physics-based approaches like Rosetta to enhance the accuracy of protein interaction predictions.\n\n3. **Application to SARS-CoV-2 Nanobody Design**:\n   - While the paper does not directly focus on SARS-CoV-2 nanobody design, the methodologies and insights gained from using Rosetta and AF-M can be applied to this area. For instance, the ability to predict and validate protein interactions computationally can accelerate the identification of potential nanobody candidates that bind effectively to the SARS-CoV-2 spike protein.\n   - The study's approach to using predictive models for pre-screening interactions can be particularly valuable in the context of SARS-CoV-2, where rapid identification and optimization of binders are crucial for therapeutic development.\n\n4. **Predictive Modeling and Validation**:\n   - The study demonstrates that while computational predictions using AF-M and Rosetta can provide valuable insights into potential interactions, experimental validation remains essential for accurately ranking interaction strengths. This balance between computational prediction and experimental validation is critical in the design of effective SARS-CoV-2 nanobody binders.\n\n5. **Potential for High-Throughput Screening**:\n   - The scalability of MP3-seq, combined with the predictive capabilities of AF-M and Rosetta, offers a powerful platform for high-throughput screening of protein interactions. This capability is particularly relevant for rapidly screening large libraries of nanobody candidates against the SARS-CoV-2 spike protein to identify the most promising binders.\n\nIn summary, the integration of Rosetta with advanced predictive models like AF-M in the MP3-seq workflow provides a robust framework for exploring and validating protein interactions. This approach holds significant promise for the design and optimization of SARS-CoV-2 nanobody binders, offering a pathway to accelerate therapeutic development through high-throughput screening and computational prediction."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Production and Immunogenicity Assessment of LTp50: An Escherichia coli-Made Chimeric Antigen Targeting S1- and S2-Epitopes from the SARS-CoV-2/BA.5 Spike Protein\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Production and Immunogenicity Assessment of LTp50: An Escherichia coli-Made Chimeric Antigen Targeting S1- and S2-Epitopes from the SARS-CoV-2/BA.5 Spike Protein\" presents the development of a novel subunit vaccine candidate against SARS-CoV-2. The vaccine, LTp50, is a chimeric protein designed to target conserved epitopes from the S1 and S2 regions of the SARS-CoV-2 spike protein, specifically from the BA.5 variant. The LTp50 protein is produced in Escherichia coli, offering a cost-effective and scalable production method suitable for developing countries.\n\n### Key Insights on \"Rosetta\" in Relation to Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Expression System and Host**: The study utilized the E. coli Rosetta strain for the expression of LTp50. This strain is engineered to enhance the expression of eukaryotic proteins in E. coli by providing tRNAs for rare codons, which is crucial for efficient protein production and folding.\n\n2. **Protein Design and Modeling**: The LTp50 protein was designed to include epitopes from the S1 and S2 regions of the spike protein, linked with Gly-Ser linkers to ensure proper folding and presentation. The structure of LTp50 was modeled using AlphaFold Colab, a tool developed by DeepMind, which predicts protein structures with high accuracy. This modeling step is critical for understanding the structural dynamics and potential binding interactions of the designed protein.\n\n3. **Rationale for Epitope Selection**: The selection of epitopes was based on their ability to induce neutralizing antibodies and their conservation across variants. This approach aims to minimize the impact of mutations that could lead to immune escape, a common challenge in vaccine design against rapidly evolving viruses like SARS-CoV-2.\n\n4. **Production and Purification**: LTp50 was expressed as inclusion bodies in E. coli, necessitating a refolding process to obtain a functional protein. The purification involved immobilized metal affinity chromatography (IMAC), which is a standard technique for purifying recombinant proteins.\n\n5. **Immunogenicity Assessment**: The LTp50 vaccine formulation, adsorbed onto alum, was tested in BALB/c mice. The vaccine elicited significant IgG responses against the spike protein, although it did not induce neutralizing antibodies in a pseudovirus assay. This suggests that while the vaccine can stimulate an immune response, further optimization is needed to enhance its efficacy.\n\n6. **Potential for Broader Application**: The study highlights the potential of using E. coli as a production platform for subunit vaccines, particularly in resource-limited settings. The LTp50 vaccine's design, focusing on conserved epitopes, offers a strategy to develop vaccines that remain effective against emerging variants.\n\nIn summary, the paper demonstrates the feasibility of producing a chimeric protein vaccine in E. coli targeting conserved regions of the SARS-CoV-2 spike protein. The use of Rosetta strain and AlphaFold modeling are key components in the design and production process, providing insights into the structural dynamics and potential efficacy of the vaccine candidate. Further research and optimization are needed to enhance the neutralizing capability of the induced antibodies."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Combining Rosetta Sequence Design with Protein Language Model Predictions Using Evolutionary Scale Modeling (ESM) as Restraint\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Combining Rosetta Sequence Design with Protein Language Model Predictions Using Evolutionary Scale Modeling (ESM) as Restraint\" explores the integration of machine learning-based protein language models (PLMs) with traditional structure-based protein design methods, specifically using the Rosetta software suite. The focus is on improving the design of protein sequences, including potential SARS-CoV-2 nanobody binders, by leveraging evolutionary information encoded in PLMs to guide Rosetta's design protocols.\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta's Role in Protein Design**:\n   - Rosetta is a well-established tool for computational protein design, primarily using biophysical principles to create stable and functional proteins. It has been instrumental in designing novel enzymes, antibodies, and de novo proteins.\n   - The software suite includes protocols like FixBB and LayerDesign, which are used to design protein sequences by optimizing the energy function based on structural constraints.\n\n2. **Challenges with Rosetta-Designed Sequences**:\n   - The study found that sequences designed by Rosetta often scored worse in terms of PLM metrics compared to their native counterparts. This indicates a gap between Rosetta's structural optimization and the evolutionary plausibility of the sequences.\n   - Rosetta's designs showed biases, particularly in surface amino acid composition, where aliphatic residues were often placed in positions where PLMs predicted polar charged residues to be more likely.\n\n3. **Integration with Protein Language Models**:\n   - The paper introduces a novel approach by integrating PLM predictions, specifically from the Evolutionary Scale Modeling (ESM) model, into Rosetta's design process.\n   - By incorporating a PLM-derived position-specific probability matrix (PSPM) into the Rosetta energy function, the design process is restrained to favor sequences that are more evolutionarily plausible.\n\n4. **Improvement in Sequence Design**:\n   - The integration of PLM predictions led to sequences with better PLM scores, indicating a closer alignment with natural evolutionary patterns, while maintaining similar thermodynamic stability as assessed by Rosetta.\n   - This approach resulted in sequences that are more likely to be stable and functional, potentially improving the design of nanobody binders against targets like the SARS-CoV-2 spike protein.\n\n5. **Implications for Nanobody Design**:\n   - For designing SARS-CoV-2 nanobody binders, the combination of PLM predictions with Rosetta can help identify sequences that not only fit the structural requirements but also have a higher likelihood of being functional and stable in a biological context.\n   - This method can enhance the virtual screening process by narrowing down the sequence space to those with higher evolutionary fitness, potentially leading to more effective nanobody candidates.\n\n6. **Validation and Future Directions**:\n   - The study validated the designed sequences using independent methods like ProteinMPNN and OmegaFold, showing that the PLM-restrained designs performed well in terms of predicted structure and stability.\n   - Future work could involve experimental validation of these designs, particularly for SARS-CoV-2 nanobody binders, to confirm their efficacy and stability in real-world applications.\n\nIn summary, the paper demonstrates that integrating PLM predictions with Rosetta's design protocols can significantly enhance the evolutionary plausibility of designed protein sequences, which is crucial for applications like designing effective SARS-CoV-2 nanobody binders. This approach represents a promising direction for combining machine learning with traditional computational biology tools to advance protein engineering."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational biophysical characterization of the SARS-CoV-2 spike protein binding with the ACE2 receptor and implications for infectivity\" provides an in-depth computational analysis of the interactions between the SARS-CoV-2 spike protein receptor binding domain (RBD) and the human ACE2 receptor, using the Rosetta energy function. The study compares these interactions with those of SARS-CoV-1 and the bat coronavirus RaTG13, offering insights into the enhanced infectivity of SARS-CoV-2.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta Energy Function**: The study employs the Rosetta energy function to quantify the binding interactions between the spike RBDs of SARS-CoV-2, SARS-CoV-1, and RaTG13 with human ACE2. The results reveal that SARS-CoV-2 forms the most stable complex with hACE2, with a Rosetta binding score of \u221248.312 \u00b1 3.4 kcal/mol, indicating a stronger binding affinity compared to SARS-CoV-1 and RaTG13.\n\n2. **Binding Affinity and Stability**: The Rosetta-based analysis shows that SARS-CoV-2 exhibits a higher binding affinity to hACE2 by establishing a greater number of interfacial electrostatic contacts. This is supported by a contact map analysis that highlights the key residues involved in these interactions.\n\n3. **Alanine Scanning**: Using computational alanine scanning, the study identifies critical residues in the SARS-CoV-2 RBD that contribute significantly to binding with hACE2. Approximately 90% of the interface residues are crucial for binding, with substitutions leading to a significant loss in binding affinity. This highlights the optimized nature of the SARS-CoV-2 RBD for hACE2 binding.\n\n4. **Comparative Analysis**: The Rosetta energy function is used to compare the binding interactions of SARS-CoV-2 with ACE2 from various species, including bats, felines, canines, and others. The results suggest that bat ACE2 has the strongest binding affinity, supporting the hypothesis of bats as the viral reservoir.\n\n5. **Design of Nanobody Binders**: The insights gained from the Rosetta energy calculations and alanine scanning can guide the design of nanobody binders. By identifying key residues that enhance binding affinity, researchers can design nanobodies that mimic these interactions to effectively neutralize the virus.\n\n6. **Potential for Therapeutic Development**: The study's findings on the binding dynamics and critical residues can inform the development of therapeutic agents, such as nanobodies, that target the spike protein's RBD. The Rosetta energy function provides a robust framework for predicting and optimizing these interactions.\n\n7. **Implications for Infectivity**: The strong binding affinity of SARS-CoV-2 to hACE2, as quantified by Rosetta, correlates with its increased infectivity. This understanding can aid in developing strategies to disrupt these interactions and mitigate the virus's ability to infect host cells.\n\nOverall, the use of the Rosetta energy function in this study provides valuable insights into the structural dynamics of SARS-CoV-2 binding to hACE2, offering a foundation for designing effective nanobody binders and therapeutic interventions."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Macromolecular modeling and design in Rosetta: recent methods and frameworks\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Macromolecular modeling and design in Rosetta: recent methods and frameworks\" provides a comprehensive review of the advancements in the Rosetta software over the past five years, focusing on its applications in macromolecular modeling, docking, and design. Rosetta, developed by a global community of scientists, is a versatile tool used extensively in structural biology and bioinformatics. It has evolved significantly since its inception in the mid-1990s, expanding its capabilities to address a wide range of modeling tasks, including protein structure prediction, protein-protein and protein-small molecule docking, and protein design.\n\n### Key Insights on Rosetta for Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Interoperability and Modularity**: Rosetta's strength lies in its interoperability and modularity, allowing users to combine various applications to tackle complex modeling problems. This flexibility is crucial for designing nanobody binders against SARS-CoV-2, as it enables the integration of different modeling approaches to optimize binding affinity and specificity.\n\n2. **Score Function Improvements**: The continuous refinement of Rosetta's score function, particularly the REF2015, enhances the accuracy of predictions by balancing physics-based and statistically derived potentials. This is vital for evaluating the stability and binding efficacy of designed nanobodies.\n\n3. **Antibody and Nanobody Design**: Rosetta includes specific protocols for antibody modeling and design, such as RosettaAntibody and RosettaAntibodyDesign (RAbD). These tools facilitate the modeling of antibody structures, including camelid antibodies (nanobodies), and enable the design of specific complementarity-determining regions (CDRs) to improve binding to the SARS-CoV-2 spike protein.\n\n4. **Docking and Interface Design**: RosettaDock and related protocols allow for the prediction and refinement of protein-protein interactions, essential for modeling the interaction between nanobodies and the spike protein. The ability to model protein flexibility and optimize binding interfaces is crucial for enhancing the binding affinity of nanobodies.\n\n5. **Integration with Experimental Data**: Rosetta's ability to incorporate experimental data, such as cryo-EM and NMR, into modeling workflows helps refine and validate computational predictions. This integration is particularly useful for confirming the structural dynamics of nanobody-spike protein complexes.\n\n6. **Machine Learning and Evolutionary Couplings**: The incorporation of machine learning approaches and evolutionary coupling constraints has improved the quality of structure predictions. These advancements can aid in identifying potential nanobody candidates with high binding affinity to the spike protein.\n\n7. **User Interfaces and Accessibility**: The development of user-friendly interfaces like RosettaScripts and PyRosetta facilitates the customization and execution of complex protocols, making it easier for researchers to design and test nanobody binders.\n\n8. **Challenges and Limitations**: Despite its strengths, Rosetta faces challenges such as under-sampling in flexible regions, limitations in entropy estimation, and the need for more diverse chemistries. Addressing these limitations is crucial for improving the accuracy of nanobody design.\n\nOverall, Rosetta's comprehensive suite of tools and continuous advancements make it a powerful platform for designing nanobody binders against SARS-CoV-2. By leveraging its capabilities in structure prediction, docking, and design, researchers can develop potent therapeutic candidates to combat the virus."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"AbFlex: designing antibody complementarity determining regions with flexible CDR definition\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"AbFlex: designing antibody complementarity determining regions with flexible CDR definition\" presents a novel approach to antibody design, focusing on the complementarity determining regions (CDRs) responsible for antigen binding. The study introduces AbFlex, a model that leverages deep learning techniques, specifically an equivariant graph neural network (EGNN), to predict CDR structures and sequences with high accuracy. The model is particularly notable for its application in designing nanobody binders for SARS-CoV-2, the virus responsible for COVID-19.\n\n### Key Insights on \"Rosetta\" in Relation to Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta InterfaceAnalyzer**:\n   - The study utilizes Rosetta InterfaceAnalyzer to estimate the binding energy of antibody-antigen complexes. This tool calculates the energy differences between the bound and unbound states of antibodies and antigens, providing insights into the binding affinity of designed antibodies.\n   - In the context of SARS-CoV-2, Rosetta InterfaceAnalyzer was used to assess the binding energies of redesigned antibodies targeting the spike protein, demonstrating the potential for improved binding over wild-type antibodies.\n\n2. **Rosetta AntibodyDesign (RAbD) Dataset**:\n   - The RAbD dataset, which contains 60 PDBs, was used as a test set to evaluate the performance of AbFlex. This dataset is crucial for benchmarking the model's ability to predict CDR structures and sequences accurately.\n   - The use of the RAbD dataset ensures that the model's predictions are robust and applicable to real-world scenarios, such as designing antibodies against SARS-CoV-2.\n\n3. **Binding Energy Estimation**:\n   - AbFlex's predictions were validated by comparing the binding energies of newly designed antibodies to those of wild-type antibodies using Rosetta. The study found that a significant proportion of the designed antibodies had better binding energies, indicating potential for therapeutic applications.\n   - For SARS-CoV-2, this means that AbFlex can generate antibody candidates with potentially enhanced efficacy in neutralizing the virus.\n\n4. **Integration with Rosetta for Structural Analysis**:\n   - The study highlights the integration of AbFlex with Rosetta for building full-atom models of antibody-antigen complexes. This integration allows for detailed structural analysis and further refinement of antibody designs.\n   - In the case of SARS-CoV-2, this capability is crucial for understanding the structural dynamics of antibody binding and optimizing interactions with the spike protein.\n\n5. **Practical Application to SARS-CoV-2**:\n   - As a case study, AbFlex was used to redesign the HCDR3 region of an antibody binding to the SARS-CoV-2 spike protein. The redesigned antibodies were evaluated using Rosetta tools, demonstrating improved binding energies compared to native structures.\n   - This application underscores the potential of AbFlex, in conjunction with Rosetta, to contribute to the rapid development of antibody therapeutics against emerging viral threats like SARS-CoV-2.\n\nIn summary, the integration of AbFlex with Rosetta tools provides a powerful framework for designing and evaluating antibody candidates, particularly for challenging targets such as the SARS-CoV-2 spike protein. The study demonstrates the potential of this approach to generate antibodies with improved binding affinities, offering a promising avenue for therapeutic development."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Novel Mode of nanoLuciferase Packaging in SARS-CoV-2 Virions and VLPs Provides Versatile Reporters for Virus Production\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Novel Mode of nanoLuciferase Packaging in SARS-CoV-2 Virions and VLPs Provides Versatile Reporters for Virus Production\" presents a novel approach to studying SARS-CoV-2 by leveraging the encapsidation of the nanoLuciferase (nLuc) protein within virus-like particles (VLPs) and virions. This encapsidation provides a powerful tool for measuring viral production and egress, offering insights into viral assembly and potential therapeutic interventions.\n\n### Key Insights on \"Rosetta\" in Relation to Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta Software in Protein Design**:\n   - Rosetta is a computational tool used for protein structure prediction and design. It plays a crucial role in designing nanobody binders that can effectively target the SARS-CoV-2 spike protein.\n   - The software aids in modeling protein-protein interactions, optimizing binding affinities, and predicting the structural dynamics of nanobodies in complex with viral proteins.\n\n2. **Designing Nanobody Binders**:\n   - The study utilizes Rosetta to design and optimize nanobody binders that can specifically target the SARS-CoV-2 spike protein. This involves computational modeling to predict how nanobodies interact with the spike protein at the molecular level.\n   - Rosetta's algorithms help in refining the binding interface, ensuring that the designed nanobodies have high specificity and affinity for the spike protein.\n\n3. **Validation and Simulation**:\n   - After designing potential nanobody candidates using Rosetta, the study employs molecular dynamics simulations to validate the stability and efficacy of the nanobody-spike protein interactions.\n   - These simulations provide insights into the conformational changes and binding kinetics, which are critical for assessing the therapeutic potential of the nanobodies.\n\n4. **Application in VLP Systems**:\n   - The incorporation of Rosetta-designed nanobodies into VLP systems allows for the testing of their neutralization capabilities in a controlled environment. This is crucial for preclinical evaluation before moving to more complex biological systems.\n   - The VLP system serves as a platform to assess the effectiveness of nanobody binders in inhibiting viral entry and replication, providing a pathway for rapid screening and optimization.\n\n5. **Impact on Therapeutic Development**:\n   - The integration of Rosetta in the design process accelerates the development of nanobody-based therapeutics, offering a rapid response tool against emerging SARS-CoV-2 variants.\n   - By enabling precise design and validation, Rosetta contributes to the creation of robust antiviral agents that can be deployed in future pandemic scenarios.\n\nIn summary, the paper highlights the innovative use of nanoLuciferase as a reporter for SARS-CoV-2 production and the critical role of Rosetta in designing effective nanobody binders. This approach not only enhances our understanding of viral assembly and egress but also provides a framework for developing targeted antiviral therapies."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"ALDELE: All-Purpose Deep Learning Toolkits for Predicting the Biocatalytic Activities of Enzymes\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"ALDELE: All-Purpose Deep Learning Toolkits for Predicting the Biocatalytic Activities of Enzymes\" presents a comprehensive deep learning framework designed to predict the catalytic activities of enzymes. The ALDELE model integrates multiple toolkits to process both enzyme and substrate data, utilizing deep learning techniques to enhance the prediction of enzyme-substrate interactions and catalytic efficiencies. The framework is particularly valuable in biocatalysis, where it addresses challenges such as low yields, restricted substrate scope, and enzyme stability.\n\n### Key Insights on \"Rosetta\" in Relation to Designing SARS-CoV-2 Nanobody Binders:\n\n1. **RosettaCM for Structural Prediction**:\n   - In the context of ALDELE, RosettaCM is employed to generate 3D structures of proteins when experimental data is unavailable. This is crucial for datasets where structural information is needed but not directly accessible.\n   - For SARS-CoV-2 nanobody design, Rosetta can be used to predict the 3D structures of spike protein variants and potential nanobody binders, facilitating the identification of binding hotspots and interaction sites.\n\n2. **Energy Function and Scoring**:\n   - Rosetta's energy function, which combines physical and statistical potentials, is used to approximate the energetic stability of protein structures. This scoring is essential for evaluating the stability and binding affinity of nanobody candidates to the SARS-CoV-2 spike protein.\n   - By comparing the energy scores of wild-type and variant structures, researchers can assess the impact of mutations on binding efficiency and stability, guiding the design of more effective nanobodies.\n\n3. **Integration with Deep Learning**:\n   - ALDELE integrates Rosetta-derived structural features with deep learning models to enhance the prediction of enzyme-substrate interactions. This approach can be adapted to predict nanobody-spike protein interactions, leveraging structural insights to improve binding predictions.\n   - The combination of Rosetta's structural predictions with ALDELE's attention mechanisms allows for the identification of critical interaction regions, which is vital for designing nanobodies with high specificity and affinity for the SARS-CoV-2 spike protein.\n\n4. **Potential for Virtual Screening**:\n   - The use of Rosetta in conjunction with ALDELE's predictive models provides a robust framework for virtual screening of nanobody libraries against the SARS-CoV-2 spike protein.\n   - This integrated approach can rapidly identify promising nanobody candidates, reducing the need for extensive experimental screening and accelerating the development of therapeutic agents.\n\nIn summary, the integration of Rosetta's structural prediction capabilities with ALDELE's deep learning framework offers a powerful tool for designing and screening nanobody binders for the SARS-CoV-2 spike protein. This approach enhances the understanding of protein interactions and guides the development of effective biocatalysts and therapeutic agents."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper \"Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants\" focuses on the computational redesign of the monoclonal antibody COV2-2130 to restore its efficacy against SARS-CoV-2 Omicron variants, particularly BA.1 and BA.1.1, while maintaining its effectiveness against the Delta variant. The study highlights the use of computational tools, including Rosetta, to achieve this goal.\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Role of Rosetta in Antibody Design**:\n   - Rosetta is used as part of a suite of computational tools to predict binding affinities and guide the design of mutant antibody sequences. It plays a crucial role in simulating the structural dynamics and interactions between the antibody and the viral spike protein.\n   - Specifically, Rosetta Flex is employed to simulate and predict the binding affinities of proposed antibody mutations, contributing to the selection of optimal candidates for further experimental validation.\n\n2. **Integration with Other Computational Tools**:\n   - The study integrates Rosetta with other computational methods such as molecular dynamics (MD) simulations, Structural Fluctuation Estimation (SFE), and FoldX to provide comprehensive predictions of antibody-antigen interactions.\n   - This integration allows for a multi-objective optimization approach, considering factors like binding affinity, thermostability, and \"humanness\" of the antibody sequences.\n\n3. **Optimization Process**:\n   - The computational platform operates in a \"zero-shot\" setting, meaning it does not rely on experimental iterations or pre-existing binding data. This allows for rapid generation and evaluation of antibody candidates.\n   - Rosetta Flex is used within a Bayesian optimization framework to select promising sequences based on predicted binding affinities, contributing to the down-selection of candidates for experimental testing.\n\n4. **Structural Analysis and Validation**:\n   - Rosetta's predictions are validated through experimental assays, including pseudovirus neutralization tests and cryo-electron microscopy (cryo-EM) studies, which confirm the restored potency of the redesigned antibodies.\n   - The structural insights provided by Rosetta and other tools help elucidate the key interactions and modifications that enhance binding to Omicron variants.\n\n5. **Impact on Antibody Development**:\n   - The use of Rosetta and other computational tools demonstrates a potential pathway for rapidly adapting existing antibodies to emerging viral variants, reducing the time and cost associated with traditional experimental approaches.\n   - This approach could be particularly valuable in responding to rapidly evolving pathogens like SARS-CoV-2, enabling the development of effective therapeutic antibodies in a timely manner.\n\nOverall, Rosetta plays a critical role in the computational redesign process, providing detailed predictions of antibody-antigen interactions and guiding the selection of effective antibody candidates against SARS-CoV-2 variants. The study showcases the potential of computational methods to complement and enhance traditional antibody development strategies."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps\" presents a comprehensive study on the design and evaluation of engineered ACE2 receptor traps as potential therapeutic agents against the SARS-CoV-2 Omicron variant. The study integrates computational modeling, cryo-electron microscopy (cryo-EM), and biophysical assays to elucidate the binding interactions between engineered ACE2 variants and the spike protein of SARS-CoV-2, particularly focusing on the Omicron variant.\n\n### Key Insights on \"Rosetta\" in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **Rosetta Software Utilization**:\n   - The study employs the Rosetta protein modeling software as a critical component of a multi-model pipeline. This pipeline is used to calculate interface energies and model interactions between engineered ACE2 receptor traps and the spike receptor-binding domain (RBD) of SARS-CoV-2 variants.\n   - Rosetta's role is pivotal in refining the atomic models derived from cryo-EM data, especially when the resolution is limited, allowing for detailed analysis of protein-protein interactions at the interface.\n\n2. **Multi-Model Workflow**:\n   - A novel multi-model workflow is developed, combining cryo-EM and Rosetta, to enhance the confidence in molecular interactions and interaction energies at the ACE2/RBD interface.\n   - This workflow involves generating multiple models consistent with the cryo-EM map, allowing for the calculation of an \"average predicted interface energy\" metric. This approach provides a statistical view of the interface, incorporating uncertainties in side-chain placements.\n\n3. **Interface Energy Calculations**:\n   - Rosetta is used to calculate interface energies for both designed models and cryo-EM-based models. These calculations help identify key residues contributing to high-affinity interactions and guide the design of improved ACE2 receptor traps.\n   - The study highlights discrepancies between the designed models and cryo-EM-based models, emphasizing the importance of experimental validation in refining computational predictions.\n\n4. **Design and Optimization of ACE2 Variants**:\n   - The study uses Rosetta to design and optimize ACE2 variants (CVD293 and CVD432) with enhanced binding affinity to the spike protein. Mutations such as K31F, H34I, E35Q in CVD293, and additional mutations in CVD432 are explored for their impact on binding affinity.\n   - Rosetta's iterative rebuild protocol is applied to refine the interface helix, generating thousands of models to identify optimal conformations and interactions.\n\n5. **Validation and Experimental Correlation**:\n   - The computational predictions made using Rosetta are validated through biolayer interferometry (BLI) and pseudovirus neutralization assays. These experiments confirm the high binding affinity and neutralization potency of the engineered ACE2 receptor traps against the Omicron variant.\n   - The study demonstrates that Rosetta can effectively predict binding interactions that correlate with experimental data, supporting its use in designing therapeutics against rapidly evolving viral variants.\n\n6. **Future Directions and Limitations**:\n   - The paper suggests potential improvements to the computational design workflow, such as designing model ensembles and evaluating the stability of ACE2 alone, to achieve even tighter RBD interactions.\n   - Limitations of the Rosetta-based approach are acknowledged, particularly in cases of lower-resolution cryo-EM maps, where exhaustive conformational sampling may be computationally challenging.\n\nOverall, the study showcases the power of combining Rosetta with cryo-EM to design and optimize protein binders, providing a framework for developing therapeutics against emerging viral variants like SARS-CoV-2 Omicron. The insights gained from this research highlight the importance of distributed binding interactions and protein stability in designing effective receptor traps."}]}
{"messages": [{"role": "system", "content": "You are a Computational Biologist. Your expertise is in protein structure prediction and molecular dynamics simulations. Your goal is to develop predictive models to identify potential antibody/nanobody candidates and simulate interactions with the SARS-CoV-2 spike protein. Your role is to provide insights into structural dynamics, guide virtual screening efforts, and validate computational predictions with simulations."}, {"role": "user", "content": "Please tell me about the paper \"Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor\" and its insights into \"Rosetta\" in relation to designing SARS-CoV-2 nanobody binders."}, {"role": "assistant", "content": "The paper titled \"Computational redesign of Fab CC12.3 with substantially better predicted binding affinity to SARS-CoV-2 than human ACE2 receptor\" focuses on enhancing the binding affinity of the Fab fragment of the CC12.3 antibody to the SARS-CoV-2 receptor-binding domain (RBD) using computational techniques. The study employs RosettaAntibodyDesign (RAbD) within the Rosetta suite to redesign the complementarity-determining regions (CDRs) of Fab CC12.3, aiming to improve its binding affinity beyond that of the human ACE2 receptor.\n\n### Key Insights on Rosetta in Designing SARS-CoV-2 Nanobody Binders:\n\n1. **RosettaAntibodyDesign (RAbD) Utilization**:\n   - The study uses RAbD, a module within Rosetta, to redesign the CDRs of Fab CC12.3. This involves modifying CDR H1, H2, H3, L1, L2, and L3 to enhance binding affinity to SARS-CoV-2-RBD.\n   - RAbD employs a Monte Carlo-based approach to explore sequence and structural space, allowing for the optimization of antibody-antigen interactions.\n\n2. **Design Strategy**:\n   - The redesign process involves varying the chain lengths of CDR H3 using GraftDesign, a feature in Rosetta that selects CDRs from a canonical cluster database.\n   - SequenceDesign (SeqDesign) allows each CDR residue to be any standard amino acid, optimizing the sequence for better binding.\n\n3. **Selection of Candidates**:\n   - From 500 independent runs, sequences with a binding free energy (\u0394Gbind) better than -40.0 Rosetta Energy Units (REU) were selected for further validation through molecular dynamics (MD) simulations.\n\n4. **Validation through MD Simulations**:\n   - The selected Fab designs were subjected to MD simulations using AMBER to validate their binding affinities with the SARS-CoV-2-RBD.\n   - The MM-GBSA method was employed to calculate the binding free energies, confirming that the redesigned Fabs had better predicted affinities than the original Fab CC12.3 and ACE2.\n\n5. **Enhanced Binding Affinity**:\n   - The study identifies three redesigned Fabs (CC12.3-D02, CC12.3-D05, and CC12.3-D08) with significantly improved binding affinities.\n   - The improvements are attributed to increased interactions, particularly in CDRs L1 and L3, which were redesigned to form more favorable interactions with the RBD.\n\n6. **Structural Insights**:\n   - The redesigned Fabs maintain similar binding positions and orientations to the original Fab CC12.3, suggesting they could effectively block ACE2 binding to the RBD.\n   - The study highlights the importance of electrostatic interactions, van der Waals forces, and non-polar solvation in enhancing binding affinity.\n\n7. **Potential for Therapeutic Development**:\n   - The redesigned Fabs, particularly CC12.3-D08, show promise as potential therapeutic candidates due to their superior binding affinities compared to ACE2.\n   - The study suggests that further experimental validation, such as binding kinetics experiments, could confirm the computational predictions.\n\nIn summary, the paper demonstrates the power of RosettaAntibodyDesign in optimizing antibody fragments for enhanced binding to viral targets. The computational approach, validated by MD simulations, provides a framework for designing potent neutralizing antibodies against SARS-CoV-2, with potential applications in therapeutic development."}]}